21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer...
15:29 , Nov 8, 2018 |  BC Innovations  |  Translation in Brief

Solid plans for CDK9

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include...
22:43 , Oct 26, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
19:30 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample and mouse studies suggest promoting the expression of KIF16B, SELENOW and TESK2 could help prevent brain metastasis in lung cancer. In patients, low expression of KIF16B, SELENOW and TESK2 in...
18:40 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Setback for Sunovion's dasotraline in ADHD

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said it received a complete response letter for dasotraline (SEP-225289) to treat ADHD. The company said FDA indicated the need for more efficacy...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Cell culture and mouse studies suggest deoxycholate-mediated PGE2 inhibition or agonism of FXR could help treat colonic injury. In a mouse model of colonic mucosal biopsy injury, PGE2 levels were higher during the...
01:40 , Aug 18, 2018 |  BioCentury  |  Regulation

Pediatric push

FDA has endorsed extrapolation of therapeutic efficacy from adults to children for new drugs to treat partial onset seizures in a draft guidance and is now discussing in public meetings whether the approach can be...
17:08 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sunovion's high-dose dasotraline meets primary in Phase III for binge eating disorder

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said the once-daily 6 mg dose of dasotraline (SEP-225289) met the primary endpoint of reducing the number of binge days, defined as days...
23:37 , Jul 20, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...